Dosing & Uses
Dosage Forms & Strengths
tablets
- 1mg (generic, Robinul)
- 1.5mg (generic)
- 2mg (generic, Robinul Forte)
tablet, oral disintegrating
- 1.7mg (Dartisla ODT)
oral solution
- 1mg/5mL (Cuvposa)
injectable solution
- 0.2mg/mL
Surgery
Preoperative reduction of saliva or intraoperative reduction of cholinergic effects
Preoperative: 4mcg/kg IM 30-60 min before surgery
Intraoperative: 0.1 mg IV; may repeat q2-3min
Neuromuscular Blockade Reversal
Prevention of muscarinic adverse effects
0.2 mg IV per 1 mg of neostigmine or 5 mg of pyridostigmine administered
Adjunct to Treatment of Peptic Ulcer
Indicated in adults to reduce symptoms of peptic ulcer as an adjunct to treatment of peptic ulcer1.7 mg PO BID/TID; not to exceed 6.8 mg/day
Use lowest effective dose to control symptoms
Switching from other oral glycopyrrolate
- Patients receiving 2 mg of another oral tablet dosage form of glycopyrrolate may be switched to 1.7 mg
Drooling (Off-label)
0.1 mg/kg PO q8-12hr; not to exceed 8 mg/day
Frey Syndrome (Orphan)
Orphan indication sponsor
- Wellesley Therapeutics, Inc; 200 Gerrard St., East Toronto, Ontario M5A 2E6; Canada
Dosing Considerations
Dartisla ODT
- Not indicated as monotherapy for treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established
- Not recommended for patients in whom a lower dosage strength of another oral glycopyrrolate product (eg, 1-mg tablet) is appropriate for initial or maintenance treatment
Dosage Forms & Strengths
tablets
- 1mg (generic, Robinul)
- 2mg (generic, Robinul Forte)
injectable solution
- 0.2mg/mL (Cuvposa)
oral solution
- 1mg/5mL
Surgery
Preoperative reduction of saliva or intraoperative reduction of cholinergic effects
1 month to 2 years (preoperative): 4-9 mcg/kg IM 30-60 min before anesthesia or when preanesthetic opioid and/or sedative administered
>2 years: 4 mcg/kg IM
Preoperative: 30-60 min before surgery
Intraoperative: May repeat q2-3min; not to exceed 0.1 mg
Drooling
FDA-approved for children with chronic, severe drooling associated with neurologic conditions (eg, cerebral palsy)
<3 years: Safety and efficacy not established
3-16 years: 0.02 mg/kg PO q8hr initially; may increase by 0.02 mg/kg q5-7days if warranted, up to 0.1 mg/kg q8hr
Not to exceed 1.5-3 mg/dose (based on weight; see Mfr info)
Control of Secretions (Off-label)
0.04-0.1 mg/kg PO q6hr
Neuromuscular Blockade Reversal
0.2 mg IV per 1 mg of neostigmine or 5 mg of pyridostigmine administered
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (1)
- umeclidinium bromide/vilanterol inhaled
glycopyrrolate, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Duplicate therapy.
Serious - Use Alternative (7)
- glucagon
glucagon increases toxicity of glycopyrrolate by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glucagon intranasal
glucagon intranasal increases toxicity of glycopyrrolate by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, glycopyrrolate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- macimorelin
glycopyrrolate, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that may blunt the growth hormone (GH) response to macrimorelin may impact the accuracy of the diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin.
- pramlintide
pramlintide, glycopyrrolate. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.
- revefenacin
revefenacin and glycopyrrolate both decrease cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects.
- secretin
glycopyrrolate decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.
Monitor Closely (95)
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .
- aclidinium
glycopyrrolate and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- amantadine
glycopyrrolate, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.
- amitriptyline
glycopyrrolate and amitriptyline both decrease cholinergic effects/transmission. Modify Therapy/Monitor Closely.
amitriptyline increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - amoxapine
glycopyrrolate and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - aripiprazole
aripiprazole increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- atenolol
glycopyrrolate increases levels of atenolol by unknown mechanism. Use Caution/Monitor.
- atropine
atropine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine IV/IM
atropine IV/IM and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna alkaloids
belladonna alkaloids and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna and opium
glycopyrrolate and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- benperidol
glycopyrrolate decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
glycopyrrolate decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.
benperidol increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - bethanechol
bethanechol increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of buprenorphine with anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
- carbachol
carbachol increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- cevimeline
cevimeline increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chlorpromazine
chlorpromazine increases toxicity of glycopyrrolate by unknown mechanism. Use Caution/Monitor.
chlorpromazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - clomipramine
glycopyrrolate and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
clomipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - clozapine
clozapine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- cyclizine
cyclizine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- cyclobenzaprine
cyclobenzaprine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- darifenacin
darifenacin and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- desipramine
desipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.
- dicyclomine
dicyclomine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- digoxin
glycopyrrolate increases levels of digoxin by unknown mechanism. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- donepezil
donepezil increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil transdermal
donepezil transdermal, glycopyrrolate. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dosulepin
glycopyrrolate and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- doxepin
glycopyrrolate and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
doxepin increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - droperidol
droperidol increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- echothiophate iodide
echothiophate iodide increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fesoterodine
fesoterodine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- flavoxate
flavoxate and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- fluphenazine
fluphenazine increases toxicity of glycopyrrolate by unknown mechanism. Use Caution/Monitor.
fluphenazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - galantamine
galantamine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- haloperidol
haloperidol increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- henbane
glycopyrrolate and henbane both decrease cholinergic effects/transmission. Use Caution/Monitor.
- homatropine
glycopyrrolate and homatropine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hyoscyamine
glycopyrrolate and hyoscyamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- hyoscyamine spray
glycopyrrolate and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- iloperidone
iloperidone increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- imipramine
glycopyrrolate and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
imipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - ipratropium
glycopyrrolate and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- levodopa
glycopyrrolate, levodopa. Other (see comment). Use Caution/Monitor. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .
- lofepramine
glycopyrrolate and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- loxapine
loxapine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- loxapine inhaled
loxapine inhaled increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
glycopyrrolate decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. - maprotiline
glycopyrrolate and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
maprotiline increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - meclizine
glycopyrrolate and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- metformin
glycopyrrolate increases toxicity of metformin by unspecified interaction mechanism. Use Caution/Monitor. May require a dose reduction.
- methscopolamine
glycopyrrolate and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- metoclopramide intranasal
glycopyrrolate will decrease the level or effect of metoclopramide intranasal by Other (see comment). Use Caution/Monitor. Coadministration of metoclopramide intranasal with drugs that impair GI motility may decrease systemic absorption of metoclopramide. Monitor for reduced therapeutic effect.
- neostigmine
neostigmine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
glycopyrrolate and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
nortriptyline increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - olanzapine
olanzapine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- oliceridine
glycopyrrolate increases toxicity of oliceridine by Other (see comment). Use Caution/Monitor. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.
- onabotulinumtoxinA
onabotulinumtoxinA and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- orphenadrine
glycopyrrolate and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin
glycopyrrolate and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
glycopyrrolate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
glycopyrrolate and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.
- paliperidone
paliperidone increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- pancuronium
glycopyrrolate and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- perphenazine
perphenazine increases toxicity of glycopyrrolate by unknown mechanism. Use Caution/Monitor.
perphenazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - physostigmine
physostigmine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pilocarpine
pilocarpine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pimozide
pimozide increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- prabotulinumtoxinA
glycopyrrolate, prabotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- pralidoxime
glycopyrrolate and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.
- prochlorperazine
prochlorperazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- promethazine
promethazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- propantheline
glycopyrrolate and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- protriptyline
glycopyrrolate and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
protriptyline increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - pyridostigmine
pyridostigmine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quetiapine
quetiapine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- rapacuronium
glycopyrrolate and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- risperidone
risperidone increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- rocuronium
glycopyrrolate and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scopolamine
glycopyrrolate and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- solifenacin
glycopyrrolate and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- succinylcholine
succinylcholine increases and glycopyrrolate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
thioridazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- thiothixene
thiothixene increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- tiotropium
glycopyrrolate and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolterodine
glycopyrrolate and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trifluoperazine
trifluoperazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- trihexyphenidyl
glycopyrrolate and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimipramine
glycopyrrolate and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
trimipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - trospium chloride
glycopyrrolate and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.
- umeclidinium bromide
umeclidinium bromide and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents
- vecuronium
glycopyrrolate and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ziprasidone
ziprasidone increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- zotepine
glycopyrrolate decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
glycopyrrolate decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (12)
- desipramine
glycopyrrolate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- dimenhydrinate
dimenhydrinate increases toxicity of glycopyrrolate by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- donepezil
donepezil decreases effects of glycopyrrolate by pharmacodynamic antagonism. Minor/Significance Unknown.
- galantamine
galantamine decreases effects of glycopyrrolate by pharmacodynamic antagonism. Minor/Significance Unknown.
- lofepramine
lofepramine increases levels of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.
- prochlorperazine
prochlorperazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.
- promazine
promazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.
- promethazine
promethazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.
- rimantadine
rimantadine increases effects of glycopyrrolate by pharmacodynamic synergism. Minor/Significance Unknown.
- thioridazine
thioridazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.
- trazodone
glycopyrrolate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- trifluoperazine
trifluoperazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Anticholinergic symptoms (mydriasis, hyperthermia, tachycardia, cardiac arrhythmia)
Dry mouth
Dry skin
Anhidrosis
Flushing
Blurred vision
Cycloplegia
Photophobia
Palpitation
Xerophthalmia
Constipation
Urinary retention
Postmarketing Reports
Angioedema
Paradoxical bronchospasm
Dysphonia
Warnings
Contraindications
Hypersensitivity to glycopyrrolate or other ingredients
Medical conditions that preclude anticholinergic therapy (eg, angle-closure glaucoma, obstructive uropathy, GI obstruction, paralytic ileus, intestinal atony of elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis, toxic megacolon, myasthenia gravis, reflux esophagitis, hiatal hernia, mitral stenosis)
Concomitant use of solid oral dosage forms of potassium chloride
Cautions
Use caution in patients with hepatic impairment
May cause urinary retention and further complicate existing renal impairment; dose adjustment may be necessary
Use caution in patients with hiatal hernia with reflux esophagitis
May worsen symptoms of prostatic hyperplasia and/or bladder neck destruction (may increase urinary retention); use with caution
Use caution in patients with autonomic neuropathy
Use caution in patients with hyperthyroidism
In ulcerative colitis, large doses may suppress intestinal motility and exacerbate an ileus or toxic magacolon; use is contraindicated in patients with ulcerative colitis
May decrease GI motility, which can result in constipation or intestinal pseudo-obstruction; intestinal pseudo-obstruction can result in abdominal distention, pain, nausea, or vomiting; if obstruction suspected, discontinue and evaluate
Incomplete mechanical intestinal obstruction may present as diarrhea, especially in patients with an ileostomy or colostomy; discontinue treatment if incomplete mechanical intestinal obstruction is suspected or if diarrhea occurs
May cause heat prostration in the presence of fever, high ambient temperature, physical exercise; to avoid heat postration; use caution in hot weather and/or exercise
May impair mental abilities to perform tasks that require mental alertness, including operating heavy machinery
Parenteral product contains benzyl alcohol; generally avoid in neonates
Pediatric patients with spastic paralysis may experience increased response to anticholinergics, increasing the potential for adverse effects; a paradoxical reaction characterized by hyperexcitability may occur in pediatric patients taking large doses; use caution
May increase risk for anticholinergic effects, confusion, and hallucinations; use caution
Pregnancy & Lactation
Pregnancy category: B
Lactation: Excretion in milk unknown; use with caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Competitively inhibits action of ACh on autonomic effectors innervated by postganglionic nerves
Inhibits salivation, tracheobronchial secretions, bradycardia, and hypotension
Absorption
Onset: 1 min (IV); 15-30 min (IM, SC)
Duration: 2-3 hr (parenteral, vagal block); 7 hr (parenteral, inhibition of salivation); 8-12 hr (PO; anticholinergic effects)
Peak plasma time: 30-45 min
Incompletely absorbed from GI tract since completely ionized
Distribution
Vd: 1.3-1.8 L/kg (children); 0.2-0.62 L/kg (adults)
Metabolism
Several metabolites
Elimination
Excretion: Mainly as unchanged drug in feces via biliary elimination and in urine
Administration
IV Incompatibilities
Additive: Methylprednisolone sodium succinate
Syringe: Chloramphenicol, dexamethasone sodium phosphate, diazepam, dimenhydrinate, methohexital, pentazocine, pentobarbital, secobarbital, sodium bicarbonate, thiopental
Unstable at pH >6
IV Compatibilities
Syringe: Atropine, hydroxyzine, lidocaine, meperidine, morphine
IV Administration
Inspect product visually to ensure there is no particulate matter
Administer at a rate of 0.2 mg over 1-2 min
For IV administration, glycopyrrolate may be administered by IM or IV without dilution
May also be administered via tubing of a running IV infusion of a compatible solution
Oral Administration
Administer 1 hr ac or 2 hr pc
High fat food reduces PO bioavailability
Oral disintegrating tablet (ODT): Using dry hands, place ODT on top of tongue; allow tablet to disintegrate and swallow without water; do not break or cut tablet
Storage
Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Glycate oral - | 1.5 mg tablet |  | |
| glycopyrrolate oral - | 1 mg tablet |  | |
| glycopyrrolate oral - | 2 mg tablet |  | |
| glycopyrrolate oral - | 1 mg tablet |  | |
| glycopyrrolate oral - | 2 mg tablet |  | |
| glycopyrrolate oral - | 1 mg tablet |  | |
| glycopyrrolate oral - | 2 mg tablet |  | |
| glycopyrrolate oral - | 2 mg tablet |  | |
| glycopyrrolate oral - | 1 mg tablet |  | |
| glycopyrrolate oral - | 1 mg tablet |  | |
| glycopyrrolate oral - | 2 mg tablet |  | |
| glycopyrrolate oral - | 1 mg tablet |  | |
| glycopyrrolate oral - | 2 mg tablet |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| glycopyrrolate injection - | 0.2 mg/mL vial |  | |
| Cuvposa oral - | 1 mg/5 mL (0.2 mg/mL) solution |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
glycopyrrolate oral
GLYCOPYRROLATE SOLUTION - ORAL
(GLYE-koe-PIR-oh-late)
COMMON BRAND NAME(S): Cuvposa
USES: Glycopyrrolate solution is used to reduce excessive drooling caused by medical conditions (such as cerebral palsy). This medication works by decreasing the amount of saliva you make. Glycopyrrolate belongs to a class of drugs known as anticholinergics.
HOW TO USE: Read the Patient and Caregiver Information Leaflet if available from your pharmacist before you start taking glycopyrrolate and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth as directed by your doctor, usually 3 times a day. Take it on an empty stomach, at least 1 hour before or 2 hours after a meal. Carefully measure the dose using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.Dosage is based on your medical condition and response to treatment. For children, dosage is also based on weight. To reduce the risk of side effects, your doctor may direct you to start this medication at a low dose and gradually increase the dose. Follow your doctor's instructions carefully.Do not increase the dose or take this drug more often without your doctor's approval. Your condition will not improve any faster and your risk of side effects will increase.Tell your doctor if your condition does not improve or if it worsens.
SIDE EFFECTS: Drowsiness, dizziness, blurred vision, dry mouth, stuffy nose, or constipation may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.To prevent constipation, eat dietary fiber, drink enough water, and exercise. You may also need to take a laxative. Ask your pharmacist which type of laxative is right for you.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: constipation that doesn't go away, nausea that doesn't go away, stomach/abdominal bloating or pain, vomiting, diarrhea, decreased sweating, dry/hot/flushed skin, fast/irregular heartbeat, mental/mood changes (such as confusion, hallucinations, agitation, nervousness, unusual excitement), difficulty urinating/inability to urinate.Get medical help right away if you have any very serious side effects, including: eye pain/swelling/redness, vision changes (such as seeing rainbows around lights at night).A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking glycopyrrolate, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: personal or family history of glaucoma (angle-closure type), problems with urination (such as urinary tract blockage, severely enlarged prostate), stomach/intestinal problems (such as chronic constipation, slow gut, intestinal blockage/infection, ulcerative colitis), myasthenia gravis, kidney problems.This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).This medication may make you sweat less, making you more likely to get heat stroke. Avoid doing things that may cause you to overheat, such as hard work or exercise in hot weather, or using hot tubs. When the weather is hot, drink a lot of fluids and dress lightly. If you overheat, quickly look for a place to cool down and rest. Get medical help right away if you have a fever that does not go away, mental/mood changes, headache, or dizziness.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to this drug's side effects, especially drowsiness, confusion, unusual excitement, constipation, and urination problems.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: potassium chloride tablets/capsules, pramlintide.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: fever, mental/mood changes (such as confusion, unusual excitement), seizures, coma.
NOTES: Do not share this medication with others.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised February 2022. Copyright(c) 2022 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
